Navigation Links
UCSF, Sanofi collaborate to find new diabetes cures
Date:1/10/2012

The University of California, San Francisco (UCSF) has signed an alliance with international pharmaceutical company Sanofi (EURONEXT: SAN and NYSE: SNY) to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes.

The $3.1 million collaboration will bring together scientists in three UCSF labs with deep understanding of the biology of beta cells insulin-producing cells that are destroyed in type 1 diabetes and often produce too little insulin in type 2 with Sanofi researchers who are experienced in developing potential drug candidates into actual therapies.

"This is a true partnership between scientists with very different strengths," said Matthias Hebrok, PhD, director of the UCSF Diabetes Center. "UCSF is known for its deep understanding of the underlying biology of diabetes, while Sanofi has great expertise in screening compounds, identifying which molecules have potential, and moving them along to develop a new drug. Such an endeavor is almost impossible to accomplish in a single academic laboratory. Thus, both partners profit from the expertise of the other group."

The alliance is the University's third collaboration with Sanofi, alongside brain trauma and oncology research launched last year, since the two signed a master agreement in January 2011 to work together in translating academic science into potential new therapies. Master agreements lay out the fundamental terms of research collaborations, align with the University's academic mission including broad publication rights, and form part of a core strategy for the UCSF Office of Innovation, Technology and Alliances to expedite that "bench-to-bedside" research.

Partnershp Combines Expertise on Both Sides

This also is the first collaboration of its kind for the UCSF Diabetes Center, extending beyond simpler, funded-research agreements to create a two-way partnership in which s
'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. UCSF, GE Healthcare team up on pioneering cord blood project
2. Dana-Farber and sanofi-aventis establish cancer research alliance
3. Sanofi-aventis enters into a research and development collaboration with UCSF
4. Institut Pasteur Korea and Sanofi open a new research collaboration to combat HBV
5. Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution
6. Animal trackers collaborate on new Google Earth for oceans
7. Springer and Senckenberg society to collaborate on life sciences and geosciences journals
8. UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine
9. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
10. Springer to collaborate with the Human Genome Organization
11. Rutgers to collaborate in $3.4 million effort to improve prostate cancer identification using MRI
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF, Sanofi collaborate to find new diabetes cures
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... A variety of end products including jet fuel, gasoline, ... existing refineries and combinations of coal and refinery by-products, ... idea is based on the coal-to-jet fuel work that ... Caroline E. Burgess Clifford, research associate at Penn State,s ...
... tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based ... transfer radical polymerization (ATRP), which will ultimately enable ... the target and to dispense the drug in ... 200 nanometers in diameter possess many unique ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
Cached Biology News:Coal-based fuels and products hit the refinery 2Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs 2Truly sick or simply scared? 2
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... will be Centerpiece to Expansion of ... Radiation Oncology Facility, ... ), a global leader in the field of radiosurgery,today announced ... Robotic Radiosurgery System to further expand treatment,offerings for its nationally ...
... 24 United,Therapeutics Corporation (Nasdaq: UTHR ) ... quarter financial results before the open of market,on ... host a half-hour teleconference on Thursday,July 31, 2008, ... accessible,by dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A ...
... VEDBAEK, Denmark, July 24 Frost & Sullivan,has announced ... 2008 Growth,Strategy Leadership Award in the molecular diagnostic market. ... the molecular diagnostic,market., Exiqon was selected for this ... leader in the field of in vitro therapy selection,testing ...
Cached Biology Technology:St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 2St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 3St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 4Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 2Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 3
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: